Pelion shareholders tender a success

Shareholders of WSE-listed pharmaceuticals group Pelion tendered 6.94 million shares of the company (37.9 percent stake), enough for the deal to go through. KIPF, along with the company's owners which controls 25.77 percent of capital and 54.13 percent voting rights, said that the deal would be valid if at least 6.54 million shares were to be sold. . KIPF will proceed to a squeeze-out in order to secure 100 percent ownership and delist the company, KIPF also said.